The latest price target for ZyVersa Therapeutics (NASDAQ:ZVSA) was reported by HC Wainwright & Co. on March 26, 2024. The analyst firm set a price target for $12.00 expecting ZVSA to rise to within 12 months (a possible 302.68% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for ZyVersa Therapeutics (NASDAQ:ZVSA) was provided by HC Wainwright & Co., and ZyVersa Therapeutics reiterated their buy rating.

There is no last upgrade for ZyVersa Therapeutics

There is no last downgrade for ZyVersa Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ZyVersa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ZyVersa Therapeutics was filed on March 26, 2024 so you should expect the next rating to be made available sometime around March 26, 2025.

While ratings are subjective and will change, the latest ZyVersa Therapeutics (ZVSA) rating was a reiterated with a price target of $12.00 to $12.00. The current price ZyVersa Therapeutics (ZVSA) is trading at is $2.98, which is out of the analyst’s predicted range.